基于中药活性成分的痛风性关节炎透皮治疗 系统

Transdermal Therapy System for Gouty Arthritis Based on Active Components of Traditional Chinese Medicine

摘要: 背景：痛风性关节炎由尿酸钠(MSU)晶体沉积诱发，口服抗炎药存在系统毒性和关节靶向性差等问题。中药活性成分具有多靶点抗炎镇痛优势，但经皮生物利用度低。本研究开发了一种负载附子生物碱、车前子苷和熟地黄多糖的温敏/pH双响应水凝胶微针系统，用于痛风性关节炎的局部治疗。目的：系统评价该中药微针的生物学效应，包括抑制MSU晶体形成、调控巨噬细胞炎症因子、以及在动物模型中的抗炎、镇痛及组织保护作用。方法：采用分层浇筑法制备双响应水凝胶微针。体外分别检测微针释放液对MSU晶体形成的抑制能力，以及对LPS诱导的RAW264.7巨噬细胞炎症因子(TNF-α、IL-1β、IL-6)的影响。建立MSU诱导的大鼠痛风性关节炎模型，评估微针贴敷后关节肿胀度、机械痛阈、滑膜组织病理学(H&E染色)、NLRP3炎症小体相关蛋白表达(免疫组化)及关节组织炎症因子水平(ELISA)。结果：熟地黄多糖纳米粒使MSU晶体产率降低至7.5% (抑制率 > 92%)，晶体尺寸减小至<1 μm。微针提取液显著抑制LPS诱导的巨噬细胞TNF-α、IL-1β和IL-6释放(抑制率65%~72%)，效果与秋水仙碱相当。在动物模型中，全成分微针贴敷24 h后关节肿胀度较模型组降低38%，72 h恢复至接近正常；机械痛阈72 h恢复至54 g，优于口服秋水仙碱组。组织学显示微针组滑膜炎症评分为0.8 (模型组3.7)，软骨侵蚀评分为0.5 (模型组3.2)。免疫组化及ELISA证实微针显著下调关节组织中NLRP3、Caspase-1和IL-1β的表达，并降低TNF-α、IL-1β和IL-6水平至接近假手术组。结论：基于附子生物碱、车前子苷和熟地黄多糖的双响应水凝胶微针通过抑制MSU结晶、阻断NLRP3炎症小体通路及下调炎症因子，快速缓解痛风性关节炎的肿胀与疼痛，效果优于口服秋水仙碱，为痛风性关节炎提供了安全、高效、按需释药的局部治疗新策略。

Abstract: Background: Gouty arthritis is triggered by the deposition of monosodium urate (MSU) crystals. Oral anti-inflammatory drugs suffer from systemic toxicity and poor joint targeting. Although active ingredients from traditional Chinese medicine possess multi-target anti-inflammatory and analgesic effects, their transdermal bioavailability is low. Herein, we developed a thermo/pH dual-responsive hydrogel microneedle (MN) system loaded with aconite alkaloids, plantainoside, and rehmannia polysaccharide for the topical treatment of gouty arthritis. Objective: To systematically evaluate the biological effects of this herbal microneedle system, including inhibition of MSU crystal formation, modulation of macrophage-derived inflammatory cytokines, and anti-inflammatory, analgesic, and tissue-protective effects in an animal model. Methods: Dual-responsive hydrogel microneedles were fabricated using a layer-by-layer casting method. The ability of the microneedle release solution to inhibit MSU crystallization was tested in vitro. The effects on LPS-induced RAW264.7 macrophage inflammatory cytokines (TNF-α, IL-1β, IL-6) were measured. A rat model of MSU-induced gouty arthritis was established. After microneedle application, joint swelling, mechanical pain threshold, synovial histopathology (H&E staining), NLRP3 inflammasome-related protein expression (immunohistochemistry), and inflammatory cytokine levels in joint tissue (ELISA) were evaluated. Results: Rehmannia polysaccharide nanoparticles reduced MSU crystal yield to 7.5% (inhibition rate > 92%) and decreased crystal size to <1 μm. MN extract significantly suppressed LPS-induced TNF-α, IL-1β, and IL-6 release from macrophages (inhibition rate 65%~72%), comparable to colchicine. In the animal model, 24 h after application of the full-component MN, joint swelling was reduced by 38% compared to the model group, and returned to near-normal levels at 72 h. Mechanical pain threshold recovered to 54 g at 72 h, superior to the oral colchicine group. Histological scores showed that the MN group had a synovitis score of 0.8 (model group: 3.7) and a cartilage erosion score of 0.5 (model group: 3.2). Immunohistochemistry and ELISA confirmed that MN significantly downregulated the expression of NLRP3, Caspase-1, and IL-1β in joint tissue, and reduced TNF-α, IL-1β, and IL-6 levels to near-sham levels. Conclusion: The dual-responsive hydrogel microneedle loaded with aconite alkaloids, plantainoside, and rehmannia polysaccharide rapidly alleviates swelling and pain in gouty arthritis by inhibiting MSU crystallization, blocking the NLRP3 inflammasome pathway, and reducing inflammatory cytokines. Its efficacy is superior to oral colchicine, offering a safe, efficient, and on-demand local delivery strategy for gouty arthritis.